Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Awiqli (Insulin Icodec) is a long-acting, once-weekly insulin analog designed to simplify the management of diabetes through extended glucose control. Its unique formulation enables a full week of basal insulin coverage with a single dose, making it an attractive option for patients seeking to reduce injection frequency without compromising glycemic stability. Whether managing type 1 or type 2 diabetes, those who buy Awiqli appreciate the flexibility and convenience offered by its sustained action profile. Awiqli helps optimize adherence in individuals requiring consistent basal insulin delivery.
| Fact Table | |
|---|---|
| Formula | C528H802N132O157S7 |
| License | FDA approved (2024) |
| Bioavailability | ~77% (subcutaneous) |
| Legal status | Prescription only |
| Chemical Name | Insulin icodec |
| Elimination half-life | ~196 hours (approximately 8 days) |
| Dosage (Strength) | 700 units/mL (once weekly) |
| Pregnancy | Consult doctor – limited human data available |
| Brands | Awiqli |
| Protein binding | Not significantly protein bound |
| PubChem CID | Not available |
| MedlinePlus | Not listed |
| ChEBI | Not available |
| ATC code | A10AE10 |
| DrugBank | DB16611 |
| KEGG | D12536 |
| Routes of administration | Subcutaneous injection |
Inject Awiqli once weekly, subcutaneously in the abdomen, thigh, or upper arm, using a rotation schedule to minimize tissue complications. Initiation should be individualized and may require overlap with prior insulin regimens under physician supervision. Blood glucose levels should be closely monitored, particularly during the first few weeks of therapy. The goal of Awiqli insulin therapy is to provide a stable background insulin level, and any dosage changes must be carefully managed by a healthcare professional.
The primary active ingredient is insulin icodec, a recombinant human insulin analog (70 U/mL). Each injection also includes zinc chloride, phenol, glycerol, and water for injection. The solution is clear and sterile, optimized for extended subcutaneous absorption.
Awiqli must be used under close clinical supervision, particularly in patients transitioning from daily basal insulins or those with comorbidities affecting insulin metabolism. The risk of hypoglycemia persists and may be influenced by dietary habits, concurrent illnesses, or medication interactions. Cost-related questions about Awiqli price should be addressed with healthcare providers or insurance representatives, as pricing can differ across regions and providers.
Awiqli is contraindicated in individuals with hypersensitivity to insulin icodec or excipients contained in the formulation. It is not indicated for emergency use in diabetic ketoacidosis or for use in pediatric populations due to a lack of sufficient data.
Possible adverse effects include:
Patients should report any side effects to their healthcare provider promptly, especially signs of low blood sugar or allergic response.
What is Awiqli (insulin icodec)?
Awiqli is a long-acting basal insulin designed for once-weekly subcutaneous injection to help manage blood sugar levels in adults with diabetes.
Who can use Awiqli?
Awiqli is approved for adults with type 2 diabetes. Its use in type 1 diabetes is limited and should be considered only when the benefits outweigh the risks.
How is Awiqli administered?
It is injected once weekly under the skin (subcutaneously), preferably on the same day each week.
What are common side effects?
The most common side effect is low blood sugar (hypoglycemia). Other possible side effects include reactions at the injection site and weight gain.
Can Awiqli be used during pregnancy or breastfeeding?
Awiqli is not recommended during pregnancy or breastfeeding. Consult your healthcare provider for alternative treatments.
How should Awiqli be stored?
Before first use, store Awiqli in the refrigerator. After first use, it can be kept at room temperature (up to 30°C) for up to 12 weeks.
What should I do if I miss a dose?
If you miss a dose, take it as soon as possible within three days after the missed dose. If more than three days have passed, skip the missed dose and resume your regular schedule.
Is Awiqli suitable for children?
Awiqli has not been studied in individuals under 18 years of age and is not recommended for pediatric use.
Can Awiqli be used with other diabetes medications?
Yes, Awiqli can be used in combination with other diabetes medications. Your healthcare provider will determine the best treatment plan for you.
What makes Awiqli different from other insulins?
Awiqli is the first once-weekly basal insulin, offering a longer duration of action compared to daily basal insulins, which may improve adherence for some patients.
